Supplement to the Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents Released
The Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents today released the following supplement to the Adult and Adolescent Treatment Guidelines:
Entecavir in Hepatitis B Virus (HBV)/HIV Co-Infected Patients
Previously, the guidelines recommended entecavir as an option for patients who required treatment for Hepatitis B virus (HBV) but not HIV infection. This recommendation was based on in vitro data showing no significant activity of entecavir against HIV-1. A recent case series of three patients who received entecavir without concomitant antiretroviral therapy reported a 1 log10 decline in HIV-RNA levels and emergence of M184V mutations in one patient who was studied in detail.
Based on these preliminary findings, the Panel recommends that:
For HBV/HIV co-infected patients, entecavir should not be used for the treatment of HBV infection without concomitant treatment for HIV.
Download the full supplement alone or with the complete Adult Guidelines in PDF or PDA format.